Kidney International Reports (Apr 2021)
POS-442 DISCOVERY OF CHK-336: A FIRST-IN-CLASS, LIVER-TARGETED, SMALL MOLECULE INHIBITOR OF LACTATE DEHYDROGENASE FOR THE TREATMENT OF PRIMARY HYPEROXALURIA
- J. COX,
- M.O. Boily,
- A. Caron,
- O. Chong,
- J. Ding,
- V. Dumais,
- S. Gaudreault,
- R. Gomez,
- J. Guthrie,
- A. King,
- R. Oballa,
- T. Sheng,
- J. Surendradoss,
- J. Wu,
- D. Powell
Affiliations
- J. COX
- Chinook Therapeutics, Research, Vancouver, Canada
- M.O. Boily
- Chinook Therapeutics, Research, Vancouver, Canada
- A. Caron
- Chinook Therapeutics, Research, Vancouver, Canada
- O. Chong
- Chinook Therapeutics, Research, Vancouver, Canada
- J. Ding
- Chinook Therapeutics, Research, Vancouver, Canada
- V. Dumais
- Chinook Therapeutics, Research, Vancouver, Canada
- S. Gaudreault
- Chinook Therapeutics, Research, Vancouver, Canada
- R. Gomez
- Chinook Therapeutics, Research, Vancouver, Canada
- J. Guthrie
- Chinook Therapeutics, Research, Vancouver, Canada
- A. King
- Chinook Therapeutics, Research, Vancouver, Canada
- R. Oballa
- Chinook Therapeutics, Research, Vancouver, Canada
- T. Sheng
- Chinook Therapeutics, Research, Vancouver, Canada
- J. Surendradoss
- Chinook Therapeutics, Research, Vancouver, Canada
- J. Wu
- Chinook Therapeutics, Research, Vancouver, Canada
- D. Powell
- Chinook Therapeutics, Research, Vancouver, Canada
- Journal volume & issue
-
Vol. 6,
no. 4
p. S192
